

UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION

FILED
U.S. DISTRICT COURT
INDIANAPOLIS DIVISION
09 JAN 28 PM 1:49
SOUTHERN DISTRICT
OF INDIANA
LAURA A. BRIGGS
CLERK

ELI LILLY AND COMPANY,)
)
 Plaintiff,)
)
 v.)
)
 INVAGEN PHARMACEUTICALS, INC.,)
)
 Defendant.)
)

Case No.
1:09-cv-0087 DFH -TAB

COMPLAINT

Plaintiff Eli Lilly and Company, (hereinafter “Lilly”) brings this action for patent infringement against Invagen Pharmaceuticals, Inc. (hereinafter “Invagen”). This action concerns patents related to Lilly’s pharmaceutical product EVISTA[®], a prescription drug widely used to treat and prevent postmenopausal osteoporosis.

Parties

1. Eli Lilly and Company is an Indiana corporation having its corporate offices and principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. Lilly is engaged in the business of research, development, manufacture, and sale of pharmaceutical products throughout the world.

2. Invagen Pharmaceuticals, Inc. is a New York corporation having its corporate offices and principal place of business at Seven Oser Avenue, Hauppauge New York, 11788. On information and belief, Invagen is engaged in the development and manufacture of generic pharmaceutical products for sale throughout the United States.

Jurisdiction and Venue

3. This is a complaint for patent infringement and for declaratory judgment of patent infringement. The jurisdiction of this Court is properly founded under 28 U.S.C. §§ 1331 and 1338(a) as well as 28 U.S.C. §§ 2201 and 2202.

4. Venue in this Court is proper under 28 U.S.C. §§ 1391 and 1400(b).

5. On information and belief, Invagen is a drug company that manufactures its products for distribution and sale throughout the United States, including substantial sales in the State of Indiana and the Southern District of Indiana. Invagen also filed its Abbreviated New Drug Application (“ANDA”) for the infringing product and issued a certification under 21 U.S.C. § 355(j)(2)(A)(vii)—the acts which give rise to the instant litigation—with knowledge that Lilly would be injured by such actions in Indiana. On information and belief, Invagen intends to directly or indirectly market and distribute the infringing product in this district upon approval, Invagen has maintained continuous and systematic contacts with Indiana, and Invagen has purposefully availed itself of the privileges of doing business under the laws of Indiana. Thus, Invagen is subject to personal jurisdiction in this judicial district.

Claim for Relief

The Patents-in-Suit

6. Lilly is the owner of U.S. Patent No. 6,458,811 (“the ’811 patent”), titled “Benzothiohenes Formulations Containing Same and Methods” (attached as **Exhibit A**), which is a valid patent, legally issued on October 1, 2002.

7. Lilly is the owner of U.S. Patent No. 6,797,719 (“the ’719 patent”), titled “Benzothiohenes, Formulations Containing Same, and Methods” (attached as **Exhibit B**), which is a valid patent, legally issued on September 28, 2004.

8. Lilly is the owner of U.S. Patent No. 6,894,064 (“the ’064 patent”), titled “Benzothiophenes, Formulations Containing Same, and Methods” (attached as **Exhibit C**), which is a valid patent, legally issued on May 17, 2005.

9. The commercial embodiment encompassed by the patents-in-suit is raloxifene hydrochloride (“raloxifene”). Lilly sells raloxifene under the trademark EVISTA[®]. The United States Food and Drug Administration (“FDA”) has approved EVISTA[®] for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer.

10. The ’811 patent, the ’719 patent, and the ’064 patent relate to the formulation of raloxifene for pharmaceutical or therapeutic purposes.

The Infringing Conduct by Defendant

11. On information and belief, Invagen filed an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”) for governmental approval to manufacture and sell raloxifene. As part of this application, Invagen filed Paragraph IV Certifications alleging that the ’811, ’719, and ’064 patents are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, or sale of the drug product described in Invagen’s ANDA.

12. The filing of the ANDA by Invagen constitutes infringement of the ’811 patent, the ’719 patent, and the ’064 patent (“the Lilly patents”).

13. Upon information and belief, Invagen did not exercise due care in analyzing the Lilly patents and presenting arguments in the paragraph IV certification, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), and Notice Letter, pursuant to 21 U.S.C. § 355(j)(2)(B)(ii).

14. As a result of Invagen's infringement of the Lilly patents, Lilly has been and will continue to be damaged unless said infringement is enjoined by this Court.

Count I - Patent Infringement of the '811 Patent

15. Lilly realleges and incorporates by reference paragraphs 1-14.

16. By submitting its ANDA under § 505(j) of the Federal Food, Drug, and Cosmetic Act for the purpose of obtaining approval to engage in the commercial manufacture, use, or sale of its raloxifene formulation before the expiration of the '811 patent, Invagen has directly infringed, induced infringement, and/or contributed to infringement of the '811 patent under 35 U.S.C. § 271(e)(2).

17. Invagen's actions constitute knowing and willful infringement of the Lilly patents.

Count II - Declaratory Judgment of Infringement of the '811 Patent

18. Lilly realleges and incorporates by reference paragraphs 1-17.

19. Invagen has filed or caused to be filed an application with the FDA, seeking authorization to import, market, use, offer for sale, and sell its raloxifene formulation for one or more indications. On information and belief, doctors prescribing the raloxifene formulation according to the indications sought by Invagen will be using such raloxifene in a manner that would infringe one or more claims of the '811 patent.

20. On information and belief, Invagen is expecting approval of its ANDA.

21. On information and belief, Invagen plans to begin marketing, selling, and offering to sell its raloxifene formulation with a product insert specifying one or more raloxifene indications soon after the FDA has approved such indications.

22. Such conduct will constitute infringement of one or more claims of the '811 patent under 35 U.S.C. § 271(a), inducement of infringement of the '811 patent under 35 U.S.C. § 271(b), and contributory infringement of the '811 patent under 35 U.S.C. § 271(c).

23. Invagen infringing activity has been and will continue to be done in willful disregard of Lilly's patent rights.

24. Invagen's infringing activity complained of herein is imminent and will begin following FDA approval of its application seeking one or more raloxifene indications.

25. As a result of the foregoing facts, there is a real, substantial, and continuing justiciable controversy between Lilly and Invagen as to liability for the infringement of the '811 patent. Invagen's actions have created in Lilly's mind a reasonable apprehension of irreparable harm and loss resulting from Invagen's threatened imminent actions.

Count III - Patent Infringement of the '719 Patent

26. Lilly realleges and incorporates by reference paragraphs 1-25.

27. By submitting its ANDA under § 505(j) of the Federal Food, Drug, and Cosmetic Act for the purpose of obtaining approval to engage in the commercial manufacture, use, or sale of its raloxifene formulation before the expiration of the '719 patent, Invagen has directly infringed, induced infringement, and/or contributed to infringement of the '719 patent under 35 U.S.C. § 271(e)(2).

28. Invagen's actions constitute knowing and willful infringement of the Lilly patents.

Count IV - Declaratory Judgment of Infringement of the '719 Patent

29. Lilly realleges and incorporates by reference paragraphs 1-28.

30. Invagen has filed or caused to be filed an application with the FDA, seeking authorization to import, market, use, offer for sale, and sell its raloxifene formulation for one or more indications. On information and belief, doctors prescribing the raloxifene formulation according to the indications sought Invagen will be using such raloxifene in a manner that would infringe one or more claims of the '719 patent.

31. On information and belief, Invagen is expecting approval of its ANDA.

32. On information and belief, Invagen plans to begin marketing, selling, and offering to sell its raloxifene formulation with a product insert specifying one or more raloxifene indications soon after the FDA has approved such indications.

33. Such conduct will constitute infringement of one or more claims of the '719 patent under 35 U.S.C. § 271(a), inducement of infringement of the '719 patent under 35 U.S.C. § 271(b), and contributory infringement of the '719 patent under 35 U.S.C. § 271(c).

34. Invagen's infringing activity has been and will continue to be done in willful disregard of Lilly's patent rights.

35. Invagen's infringing activity complained of herein is imminent and will begin following FDA approval of its application seeking one or more raloxifene indications.

36. As a result of the foregoing facts, there is a real, substantial, and continuing justiciable controversy between Lilly and Invagen as to liability for the infringement of the '719 patent. Invagen's actions have created in Lilly's mind a reasonable apprehension of irreparable harm and loss resulting from Invagen's threatened imminent actions.

Count V - Patent Infringement of the '064 Patent

37. Lilly realleges and incorporates by reference paragraphs 1-36.

38. By submitting its ANDA under § 505(j) of the Federal Food, Drug, and Cosmetic Act for the purpose of obtaining approval to engage in the commercial manufacture, use, or sale of its raloxifene formulation before the expiration of the '064 patent, Invagen has directly infringed, induced infringement, and/or contributed to infringement of the '064 patent under 35 U.S.C. § 271(e)(2).

39. Invagen's actions constitute knowing and willful infringement of the Lilly patents.

Count VI - Declaratory Judgment of Infringement of the '064 Patent

40. Lilly realleges and incorporates by reference paragraphs 1-39.

41. Invagen has filed or caused to be filed an application with the FDA, seeking authorization to import, market, use, offer for sale, and sell its raloxifene formulation for one or more indications. On information and belief, doctors prescribing the raloxifene formulation according to the indications sought by Invagen will be using such raloxifene in a manner that would infringe one or more claims of the '064 patent.

42. On information and belief, Invagen is expecting approval of its ANDA.

43. On information and belief, Invagen plans to begin marketing, selling, and offering to sell its raloxifene formulation with a product insert specifying one or more raloxifene indications soon after the FDA has approved such indications.

44. Such conduct will constitute infringement of one or more claims of the '064 patent under 35 U.S.C. § 271(a), inducement of infringement of the '064 patent under 35 U.S.C. § 271(b), and contributory infringement of the '064 patent under 35 U.S.C. § 271(c).

45. Invagen's infringing activity has been and will continue to be done in willful disregard of Lilly's patent rights.

46. Invagen's infringing activity complained of herein is imminent and will begin following FDA approval of its application seeking one or more raloxifene indications.

47. As a result of the foregoing facts, there is a real, substantial, and continuing justiciable controversy between Lilly and Invagen as to liability for the infringement of the '064 patent. Invagen's actions have created in Lilly's mind a reasonable apprehension of irreparable harm and loss resulting from Invagen's threatened imminent actions.

Relief Requested

Wherefore, Lilly prays for judgment and relief including:

- (A) A declaration that United States Patent Nos. 6,458,811, 6,797,719, and 6,894,064 are valid and enforceable;
- (B) A declaration that Invagen will infringe one or more claims of United States Patent Nos. 6,458,811, 6,797,719, and 6,894,064 by its threatened acts of importation, use, offering to sell, and sale of its raloxifene formulation drug product prior to expiration of said patents;
- (C) A declaration that the effective date of any approval of Invagen's raloxifene formulation drug product is not to be earlier than the latest date of expiration of United States Patent Nos. 6,458,811, 6,797,719, and 6,894,064 under 35 U.S.C. § 271(e)(4)(A);
- (D) A declaration that Invagen has no legal or equitable defense to Lilly's allegations of infringement;
- (E) A permanent injunction pursuant to 35 U.S.C. § 283, enjoining Invagen and its officers, agents, servants, employees, privies, and others acting for, on behalf of, or in


concert with any of them from infringing any claims of the Lilly patents under 35 U.S.C. § 271(e)(4)(B);

(F) An accounting and award of damages incurred by Lilly as a result of Invagen's infringement if there has been commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States under 35 U.S.C. § 271(e)(4)(C);

(G) An award declaring this case exceptional pursuant to 35 U.S.C. § 285 and granting Lilly its attorneys' fees in pursuing this case; and

(H) Such other and further equitable relief as this Court may deem just and proper.

Date: January 28, 2009



Jan M. Carroll, No. 4187-49
BARNES & THORNBURG LLP
11 South Meridian Street
Indianapolis, Indiana 46204
Telephone: (317) 236-1313
Facsimile: (317) 231-7433

Attorney for Plaintiff
ELI LILLY AND COMPANY